All In Biotech

Drug Trial Radar · NCT07768254

A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HX15001 Injection Combined With Etrasimod Tablets in the Treatment of Moderate-severe Ulcerative Colitis: an Open-label, Exploratory Clinical Trial

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Apr 15, 2028

Study completion Apr 15, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HX15001 injection combined with Etrasimod tablets in participants with moderately to severely active ulcerative colitis (UC).

Conditions

  • Colitis, Ulcerative

Interventions

  • Biological: HX15001Drug

    Dose 1: HX15001

  • Biological: HX15001Drug

    Dose 2: HX15001

  • Biological: HX15001Drug

    Dose 3: HX15001

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint in the study is the rate of participants with adverse events , serious adverse events, adverse events leading to study withdrawal, and clinically significant abnormalityes in vital signs, ECG, and laboratory test values.Time frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The first affiliated hospital of Anhui medical university

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.